Tfpi inhibitors and methods of use
AssigneesBaxter Healthcare S.A., Baxter International Inc.
InventorsMichael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
Life of this patent
Estimating the term…
Abstract
The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
Claims35
-32. (canceled)
A peptide that binds TFPI, comprising the following structure of formula V:
- X2001-X2002-X2003-X2004-X2005-X2006-[X2007-X2008-X2009-X2010-X2011-X2012-X2013-X2014-X2015-X2016-X2017-X2018]-X2019-X2020-X2021-X2022-X2023 (V) (SEQ ID NO:
- 3118)
- wherein X2001 is either present or absent, whereby in case X2001 is present it is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, P, R, S, T, V and W;
- wherein X2002 is either present or absent, whereby in case X2002 is present it is an amino acid selected from the group consisting of A, D, E, F, G, H, I, K, L, M, P, R, S, T, V and W;
- wherein X2003 is an amino acid selected from the group consisting of A, F, I, K, L, R, S, T, V, W and Y;
- wherein X2004 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V and W;
- wherein X2005 is W;
- wherein X2006 is an amino acid selected from the group consisting of F, H, I, K, L, R, V and W;
- wherein X2007 is an amino acid selected from the group consisting of C, Hcy, Dap and K, preferably selected from the group consisting of C and Hcy;
- wherein X2008 is an amino acid selected from the group consisting of A, G, R, S and T;
- wherein X2009 is an amino acid selected from the group consisting of a, A, I, K, L, M, m, Nle, p, R, Sem and V;
- wherein X2010 is an amino acid selected from the group consisting of A, G, I, K, L, P, R, S, T and V;
- wherein X2011 is an amino acid selected from the group consisting of D, E, G, S, and T;
- wherein X2012 is an amino acid selected from the group consisting of A, a, D, d, E, e, F, f, G, I, K, k, L, l, M, m, Nle, nle, P, p, R, r, S, s, Sem, T, t, V, v, W and w;
- wherein X2013 is an amino acid selected from the group consisting of A, D, d, E, e, F, G, I, K, L, R, S, s, T, V and W;
- wherein X2014 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, R, S, T, V and W;
- wherein X2015 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, M, Nle, R, S, T, V and W;
- wherein X2016 is an amino acid selected from the group consisting of A, D, E, F, I, K, L, M, Nle, R, S, Sem, T, V, W and Y;
- wherein X2017 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y;
- wherein X2018 is an amino acid selected from the group consisting of C and D, preferably C;
- wherein X2019 is an amino acid selected from the group consisting of A, F, I, L, S, T, V and W;
- wherein X2020 is an amino acid selected from the group consisting of F and W;
- wherein X2021 is an amino acid selected from the group consisting of I, L and V;
- wherein X2022 is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, P, R, S, T, V, and W;
- wherein X2023 is either present or absent, whereby in case X2023 is present it is an amino acid selected from the group consisting of A, D, E, F, G, I, K, L, R, S, T, V, W and Y;
- and
- wherein the peptide comprises as a cyclic structure generated by a linkage between X2007 and X2018.
(canceled)
-40. (canceled)
A peptide that binds TFPI, comprising the following structure of formula (VI):
- X2001-X2002-F/Y-K-W-F/H-[C-X2008-MN-X2010-D-X2012-X2013-G-I/T-X2016-SIT-C]-A/V-W-V-X2022-X2023 (VI) (SEQ ID NO:
- 3119)
- wherein X2001, X2002 and X2023 are each independently present or absent, wherein, if any of X2001, X2002 and X2023 is present, any of X2001, X2002 and X2023 is independently selected from any amino acid;
- and
- wherein X2008, X2010, X2012, X2013, X2016 and X2022 are each independently selected from any amino acid.
(canceled)
-51. (canceled)
A peptide that binds TFPI comprising an amino acid sequence of at least 60% identity to the sequence of formula VII:
- (SEQ ID NO:
- 1040)
- Ac-FYYKWH[CGMRDMKGTMSC]AWVKF-NH2 (VII)
(canceled)
A peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs:
- 1001-1210 and 1213-1293.
A peptide that binds TFPI, comprising the following structure of formula (VIII):
- X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011-X3012-X3013-X3014-X3015-X3016-X3017-X3018-X3019-X3020-X3021 (VIII) (SEQ ID NO:
- 3120):
- wherein X3001 is either present or absent, whereby in case X3001 is present it is an amino acid selected from the group consisting of A, C, D, F, G, I, K, L, M, N, P, Q, R, S, T, W, E, H and Y;
- wherein X3002 is either present or absent, whereby in case X3002 is present it is an amino acid selected from the group consisting of A, C, D, F, H, K, M, N, P, R, S, T, W, Y, G, I and L;
- wherein X3003 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, I, K, L, M, N, P;
- Q, R, S, T, W and Y;
- wherein X3004 is an amino acid selected from the group consisting of A, D, E, F, G, H, L, M, N, Q, R, S, T, V, W, Y and P;
- wherein X3005 is an amino acid selected from the group consisting of C, D, F, G, H, I, K, L, M, N, P, R, S, T, V, W and Y;
- wherein X3006 is an amino acid selected from the group consisting of A, W, C, K, P, R and H;
- wherein X3007 is an amino acid selected from the group consisting of Q, A, C, F, G, H, I, K, L, N, R, S, T, W and Y;
- wherein X3008 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, P, Q, R, S, T, V, W, Y and I;
- wherein X3009 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, R, S, T, V, W, Y and K;
- wherein X3010 is an amino acid selected from the group consisting of A, C, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y;
- wherein X3011 is an amino acid selected from the group consisting of A, G, I, K, L, M, N, Q, R, S, T, V, W, Y, C, F and H;
- wherein X3012 is an amino acid selected from the group consisting of A, C, H, I, K, L and R;
- wherein X3013 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, R, S, V, W, Y and I;
- wherein X3014 is an amino acid selected from the group consisting of A, C, F, G, H, I, L, M, N, Q, R, S, T, V, W, Y and K;
- wherein X3015 is an amino acid selected from the group consisting of A, K and R;
- wherein X3016 is an amino acid selected from the group consisting of A, F, K and R;
- wherein X3017 is an amino acid selected from the group consisting of A, C, F, G, I, K, L, N, Q, R, S, T, V, W, Y, H, A and M;
- wherein X3018 is an amino acid selected from the group consisting of A, C, F, I, K, L, M, Q, R, V, W and Y;
- wherein X3019 is an amino acid selected from the group consisting of A, C, D, E, F, G, H, K, L, N, P, Q, R, V, W, Y and I;
- wherein X3020 is an amino acid selected from the group consisting of A, C, F, G, H, K, L, M, N, Q, R, V, W, Y, I and P;
- and
- wherein X3021 is an amino acid selected from the group consisting of A, C, H, I, K, L, M, N, P, Q, R, T, V, W, Y, F and G.
(canceled)
-62. (canceled)
A peptide that binds TFPI, comprising the following structure of formula (IX):
- X3001-X3002-X3003-X3004-X3005-X3006-X3007-X3008-X3009-X3010-X3011-H—X3013-X3014-K/R—R—X3017-X3018-X3019-X3020-X3021 (IX) (SEQ ID NO:
- 3121)
- wherein X3001 and X3002 are independently either present or absent, wherein, if X3001 and/or X3002 are present, X3001 and/or X3002 are independently selected from any amino acid, and
- wherein X3003, X3004, X3005, X3006, X3007, X3008, X3009, X3010, X3011, X3013, X3014, X3017, X3018, X3019, X3020 and X3021 are each independently selected from any amino acid.
-82. (canceled)
A peptide that binds TFPI, comprising an amino acid sequence of at least 60% identity to the sequence of formula (X):
- (SEQ ID NO:
- 223)
- Ac-GYASFPWFVQLHVHKRSWEMA-NH2 (X).
-85. (canceled)
A peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs:
- 2001-2126, 2128-2296, and 2298-2498.
A peptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs:
- 3001-3048, 3051-3053, 3055, 3057-3064, and 3066-3108.
-89. (canceled)
-94. (canceled)
A method for treating a blood coagulation disorder in a subject, the method comprising administering to the subject a peptide that inhibits TFPI activity, wherein the peptide is administered in an amount sufficient to treat the blood coagulation disorder in the subject.
(canceled)
-105. (canceled)
-133. (canceled)
Dependencies are inferred from the claim text.